IGM Biosciences be acquired by Concentra for $1.247 in cash per share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2025
0mins
Merger Agreement: IGM Biosciences has entered into a definitive merger agreement with Concentra Biosciences, which will acquire IGM for $1.247 per share in cash and additional contingent value rights related to the company's net cash and product candidates.
Board Approval: The Board of Directors of IGM Biosciences unanimously supports the acquisition, deeming it beneficial for all stockholders and has approved the merger and associated transactions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
